New gel aims to stop chemo side effect that makes hands hurt
NCT ID NCT07457671
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a gel called TAR-0520 to see if it can prevent hand-foot syndrome, a painful skin reaction caused by the chemotherapy drug capecitabine. About 25 people with breast or colorectal cancer will apply the gel to their hands twice daily for 12 weeks. Their feet will not be treated and will serve as a comparison. The goal is to check if the gel is safe and reduces the severity of hand-foot syndrome.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAR-0520 gel
What this could lead to
If it works, this could point toward a way to prevent painful hand-foot syndrome in cancer patients taking capecitabine, improving their quality of life.
What could go wrong
This is a small, early-phase study with only 25 people. It may not show clear benefit, and the gel could cause local skin reactions or not reduce symptoms enough to matter.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- CG-100 Bypass Device for Colorectal Cancer (NCT05632744)
- NIR Device for Breast Flap Perfusion Study (NCT07680296)
- Long-Term Heart Effects of Anthracycline in Brea NCT07680855
- Trastuzumab + RAD001 for HER2+ Breast Cancer NCT00317720
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- Cognitive Stimulation for Elderly Breast Cancer NCT04261153
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instiut Paoli-Calmettes
Marseille, 13009, France
Contact Phone: •••-•••-••••